Cancers· 2026Q1
Increasing H3K9 Methylation Level Reduces the Proliferation of Leukemic Stem Cells
- 0citations
- Q1SCImago
- 2026year
Short summary
Increasing H3K9 methylation levels significantly reduces the proliferation of leukemic stem cells (LSCs) in both young and aged murine and patient-derived samples.
AI-generated from the title and abstract; the full text is not read.
Key points
- H3K9 methylation levels are altered during aging of hematopoietic stem cells and are associated with a pre-malignant phenotype.
- Low H3K9 methylation is necessary for leukemic cells to maintain their proliferative capacity in vitro.
- Increasing H3K9 methylation reduces leukemogenesis in both young and aged murine and patient-derived leukemic cells.
AI-generated from the title and abstract; the full text is not read.
Abstract
Background/Objectives: Genetic and epigenetic alterations accumulate throughout life in hematopoietic stem and progenitor cells (HSPCs), leading to an increased risk of age-related hematological malignancies, such as acute myeloid leukemia (AML). While a few epigenetic drugs have entered clinical practice, studies focusing on histone post-translational modifications (PTMs) altered in AML remain limited. Methods: Here, we used murine HSPCs, murine AML mouse models, human leukemic cell lines, and leukemic patient samples to investigate whether targeting the methylation of histone 3 at lysine 9 (H3K9 methylation) affects HSPCs upon aging and leukemogenesis and might represent a possible target. Results: Our data show that H3K9 methylation changes upon aging in HSPCs and is linked to a pre-malignant phenotype. Low levels of H3K9 methylation in leukemic cells are required to maintain proliferative capacities in vitro. Increasing H3K9 methylation reduces the leukemogenesis of both young and aged murine and patient-derived leukemic cells. Conclusions: Thus, H3K9 methylation might be a potential and selective therapeutic target in AML patients.
The authors' abstract, as published at the source. Cancers, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hematology
HematologyMedicine